Nektar Therapeutics (NKTR)
NKTR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/0001193125-26-104547-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NKTR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000906709 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $55.2M |
| Net income | -$164.1M |
| Operating income | -$140.1M |
| Net margin | -297.1% |
| Operating margin | -253.7% |
| Revenue growth | -43.9% |
| Cash | $15.1M |
| Total assets | $280.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 22.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-13 |
| Cash and burn | $34.7M cash; operating cash flow -$64.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 34,214,683 (2026-11-06); 20,341,589 a year earlier; 190,770,566 three years earlier. 3y figure adjusted for splits (1-for-15 overall). | Cover page 2026-11-06 |
| Reverse splits, 3 years | 1; latest 1-for-15 on 2025-06-09 | Source 2025-06-09 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 5 424B5 takedowns, 5 at the market | Latest 2026-05-08 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2026-04-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $2.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $9.4M | -$55.7M | -$71.9M | $34.7M | No debt tags | $52.2M | 10-Q 2026-11-13 |
| Q2 2026 2026-06-30 | $10.1M | -$40.6M | -$75.8M | $39.3M | No debt tags | $54.6M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $10.9M | -$44.9M | -$44.3M | $149.6M | No debt tags | $55.6M | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $21.8M | -$36.1M | -$65.0M | $15.1M | No debt tags | $55.2M | 10-K 2026-03-13 |
| Q3 2025 2025-09-30 | $11.8M | -$35.5M | -$48.8M | $41.0M | No debt tags | $62.6M | 10-Q 2026-11-13 |
| Q2 2025 2025-06-30 | $11.2M | -$41.6M | -$45.7M | $43.0M | No debt tags | $74.9M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $10.5M | -$50.9M | -$49.1M | $38.9M | No debt tags | $87.2M | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $29.2M | $7.3M | -$46.2M | $44.3M | No debt tags | $98.4M | 10-K 2026-03-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-08 |
| Latest annual report | 10-K | 2026-03-13 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.0% |
| 1 month | -1.7% |
| 3 months | -50.9% |
| Year to date | -11.8% |
| 1 year | -30.9% |
| From 52-week high | -62.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AMPH | Amphastar Pharmaceuticals Inc. | $29.17 | -0.68% | $1.2B |
| AAPG | Ascentage Pharma Group International American Depository Shares | $13.29 | -9.10% | $1.2B |
| SLN | Silence Therapeutics Plc American Depository Share | $19.80 | -0.15% | $1.2B |
| MNKD | MannKind Corporation | $3.96 | -4.24% | $1.3B |
| GHRS | GH Research PLC | $18.75 | -1.83% | $1.3B |
| MLYS | Mineralys Therapeutics Inc. | $14.53 | -5.22% | $1.3B |
| OMER | Omeros Corporation | $16.68 | -4.63% | $1.2B |
| OPK | OPKO Health Inc. | $1.62 | -3.57% | $1.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier